BioStealthAI today announced that the USPTO (U.S. Patent and Trademark Office) has issued a Notice of Allowance for the company’s Touchable® Cardiovascular Surfaces (TCS™) platform. The allowed U.S. patent complements BioStealthAI’s granted patents in Great Britain and China, further strengthening the company’s IP position in distributed photonic sensing integrated into everyday surfaces.

TCS™ enables robust, morphology-faithful PPG capture from surfaces such as notebook palmrests and trackpads, peripherals, and steering wheels, supporting higher-fidelity vitals acquisition in real-world use. BioStealthAI will announce the U.S. patent number upon issuance and will continue prosecution of follow-on filings to broaden protection for additional platform features.

In parallel, BioStealthAI is advancing technical discussions with leading notebook OEMs regarding palmrest and trackpad integrations of TCS™. (Partner details will be shared when programs become public.)

About BiostealthAI
BioStealthAI develops TCS™—Touchable® Cardiovascular Surfaces, a platform for photonic sensing surfaces embedded into everyday devices. The company focuses on enabling reliable, PPG waveform capture from surfaces such as notebook palmrests/trackpads and other human-interface elements, providing developers with robust signals for downstream analytics.

Media / Partner enquiries: press@biostealth.ai